Results 261 to 270 of about 1,151,684 (305)
Some of the next articles are maybe not open access.
Hormone Research in Paediatrics, 2007
<i>Background:</i> Pituitary tumors are common and usually grow insidiously over many years. Rarely fatal, treatment still requires multiple cytoreductive surgeries and/or radiation therapy with its attendant side effects. As a disease process of regulatory pathways, pituitary tumors offer numerous potential therapeutic targets, and many ...
openaire +2 more sources
<i>Background:</i> Pituitary tumors are common and usually grow insidiously over many years. Rarely fatal, treatment still requires multiple cytoreductive surgeries and/or radiation therapy with its attendant side effects. As a disease process of regulatory pathways, pituitary tumors offer numerous potential therapeutic targets, and many ...
openaire +2 more sources
Targeting Glioblastoma Tumor Microenvironment
2020Glioblastoma, also referred to as glioblastoma multiforme (GBM), is an aggressive type of brain cancer. The prognosis for GBM is poor with an average medium survival rate of 12-15 months. GBM is highly challenging to treat due to neural stem cells phenotypic variations.
Megan, Butler +2 more
openaire +2 more sources
Tumor antigen targets and tumor immunotherapy
Frontiers in Bioscience, 2006Tumor immunology and immunotherapy attempt to use the exquisite specificity and lytic capability of the immune system to treat malignant disease with a minimum of damage to normal tissue. Increasing knowledge of the identity of tumor antigens should point the way to effective therapeutic vaccines or more specific immunotherapeutic strategies.
openaire +2 more sources
Tumor‐Targeted Catalytic Immunotherapy
Advanced MaterialsAbstractCancer immunotherapy holds significant promise for improving cancer treatment efficacy; however, the low response rate remains a considerable challenge. To overcome this limitation, advanced catalytic materials offer potential in augmenting catalytic immunotherapy by modulating the immunosuppressive tumor microenvironment (TME) through precise ...
En‐Li Yang +5 more
openaire +2 more sources
Colloidal Systems for Tumor Targeting
Hybridoma, 1997The potential and limitations of targeted delivery of anticancer agents with colloidal particulate carriers is the subject of this contribution. Because over the years liposomes have gained the most attention as carrier system in the category of colloidal carrier systems, this paper focuses on the utility of the liposomal system for tumor targeting. It
Storm, G., Crommelin, D.J.A.
openaire +3 more sources
2021
Monoclonal antibodies are specific molecules with a high affinity for the cell surface proteins. Long circulation time in blood makes them unsuitable for imaging as well as therapy. The process of protein engineering improves antibody’s pharmacokinetics retaining the property of affinity and specificity.
Dhritiman Chakraborty +2 more
openaire +1 more source
Monoclonal antibodies are specific molecules with a high affinity for the cell surface proteins. Long circulation time in blood makes them unsuitable for imaging as well as therapy. The process of protein engineering improves antibody’s pharmacokinetics retaining the property of affinity and specificity.
Dhritiman Chakraborty +2 more
openaire +1 more source
Combination Vascular Targeted and Tumor Targeted Radioimmunotherapy
Cancer Biotherapy and Radiopharmaceuticals, 1999Rat MAb 201B, which binds to murine thrombomodulin, can deliver up to 50% of the injected dose of attached radioisotopes to the lung vascular endothelium. We have shown previously that intravenous injection of about 30 microCi of 213Bi-MAb 201B, which delivers about 15 Gy of alpha irradiation to the lung, is capable of eradicating small lung colonies ...
S J, Kennel +5 more
openaire +2 more sources
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2007
To overcome the hurdles of conventional tumor therapy, efforts have been directed to wards the development of anti-angiogenic agents, since the growth of solid tumors is dependent on their capacity to acquire a blood supply. More recently, it has become apparent that the targeted destruction of the established tumor vasculature or the delivery of ...
Dragan Grabulovski, Dario Neri
openaire +3 more sources
To overcome the hurdles of conventional tumor therapy, efforts have been directed to wards the development of anti-angiogenic agents, since the growth of solid tumors is dependent on their capacity to acquire a blood supply. More recently, it has become apparent that the targeted destruction of the established tumor vasculature or the delivery of ...
Dragan Grabulovski, Dario Neri
openaire +3 more sources
Branched Neurotensin for Tumor Targeting
2010Introduction One of the major problems in classic chemotherapy is the non-specific toxicity of most anticancer agents against normal cells. The specific targeting of tumors has been the main challenge in research on cancer therapy and diagnosis.
FALCIANI C. +5 more
openaire +3 more sources
Cancer remains a global health challenge, with conventional treatments often limited by toxicity and specificity. Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized cancer treatment by modifying T cells to target tumor antigens, showing significant success in hematological malignancies like acute lymphoblastic leukemia and diffuse large ...
Safiya Mehraj, Shazia Ali
openaire +1 more source
Safiya Mehraj, Shazia Ali
openaire +1 more source